Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Identifieur interne : 000446 ( Main/Exploration ); précédent : 000445; suivant : 000447Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Auteurs : Ji Eun Park [Corée du Sud] ; Joonyoung Park [États-Unis] ; Yearin Jun [Corée du Sud] ; Yunseok Oh [Corée du Sud] ; Gongmi Ryoo [Corée du Sud] ; Yoo-Seong Jeong [Corée du Sud] ; Hytham H. Gadalla [États-Unis] ; Jee Sun Min [Corée du Sud] ; Jung Hwan Jo [Corée du Sud] ; Myung Geun Song [Corée du Sud] ; Keon Wook Kang [Corée du Sud] ; Soo Kyung Bae [Corée du Sud] ; Yoon Yeo [États-Unis] ; Wooin Lee [Corée du Sud]Source :
- Journal of controlled release : official journal of the Controlled Release Society [ 1873-4995 ] ; 2019.
Descripteurs français
- KwdFr :
- Albumines (composition chimique), Animaux (MeSH), Antinéoplasiques (composition chimique), Antinéoplasiques (usage thérapeutique), Cyclodextrines (composition chimique), Distribution tissulaire (MeSH), Femelle (MeSH), Humains (MeSH), Inhibiteurs du protéasome (composition chimique), Inhibiteurs du protéasome (usage thérapeutique), Libération de médicament (MeSH), Nanoparticules (composition chimique), Oligopeptides (composition chimique), Oligopeptides (pharmacocinétique), Oligopeptides (usage thérapeutique), Poloxamère (composition chimique), Propriétés de surface (MeSH), Préparation de médicament (MeSH), Solubilité (MeSH), Souris (MeSH), Souris de lignée BALB C (MeSH), Stabilité de médicament (MeSH), Transport biologique (MeSH), Tumeurs du sein (traitement médicamenteux), Vecteurs de médicaments (composition chimique).
- MESH :
- composition chimique : Albumines, Antinéoplasiques, Cyclodextrines, Inhibiteurs du protéasome, Nanoparticules, Oligopeptides, Poloxamère, Vecteurs de médicaments.
- pharmacocinétique : Oligopeptides.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs du protéasome, Oligopeptides.
- Animaux, Distribution tissulaire, Femelle, Humains, Libération de médicament, Propriétés de surface, Préparation de médicament, Solubilité, Souris, Souris de lignée BALB C, Stabilité de médicament, Transport biologique.
English descriptors
- KwdEn :
- Albumins (chemistry), Animals (MeSH), Antineoplastic Agents (chemistry), Antineoplastic Agents (therapeutic use), Biological Transport (MeSH), Breast Neoplasms (drug therapy), Cyclodextrins (chemistry), Drug Carriers (chemistry), Drug Compounding (MeSH), Drug Liberation (MeSH), Drug Stability (MeSH), Female (MeSH), Humans (MeSH), Mice (MeSH), Mice, Inbred BALB C (MeSH), Nanoparticles (chemistry), Oligopeptides (chemistry), Oligopeptides (pharmacokinetics), Oligopeptides (therapeutic use), Poloxamer (chemistry), Proteasome Inhibitors (chemistry), Proteasome Inhibitors (therapeutic use), Solubility (MeSH), Surface Properties (MeSH), Tissue Distribution (MeSH).
- MESH :
- chemical , chemistry : Albumins, Antineoplastic Agents, Cyclodextrins, Drug Carriers, Oligopeptides, Poloxamer, Proteasome Inhibitors.
- chemical , pharmacokinetics : Oligopeptides.
- chemical , therapeutic use : Antineoplastic Agents, Oligopeptides, Proteasome Inhibitors.
- chemistry : Nanoparticles.
- drug therapy : Breast Neoplasms.
- Animals, Biological Transport, Drug Compounding, Drug Liberation, Drug Stability, Female, Humans, Mice, Mice, Inbred BALB C, Solubility, Surface Properties, Tissue Distribution.
Abstract
Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbacks. We investigated whether a nanocrystal (NC) formulation can address these issues and enhance anticancer efficacy of CFZ against breast cancer. The surface of NC was coated with albumin in order to enhance the formulation stability and drug delivery to tumors via interactions with albumin-binding proteins located in and near cancer cells. The novel albumin-coated NC formulation of CFZ (CFZ-alb NC) displayed improved metabolic stability and enhanced cellular interactions, uptake and cytotoxic effects in breast cancer cells in vitro. Consistently, CFZ-alb NC showed greater anticancer efficacy in a murine 4T1 orthotopic breast cancer model than the currently used cyclodextrin-based formulation. Overall, our results demonstrate the potential of CFZ-alb NC as a viable formulation for breast cancer therapy.
DOI: 10.1016/j.jconrel.2019.04.006
PubMed: 30954620
PubMed Central: PMC6638563
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.</title><author><name sortKey="Park, Ji Eun" sort="Park, Ji Eun" uniqKey="Park J" first="Ji Eun" last="Park">Ji Eun Park</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Park, Joonyoung" sort="Park, Joonyoung" uniqKey="Park J" first="Joonyoung" last="Park">Joonyoung Park</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Jun, Yearin" sort="Jun, Yearin" uniqKey="Jun Y" first="Yearin" last="Jun">Yearin Jun</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Oh, Yunseok" sort="Oh, Yunseok" uniqKey="Oh Y" first="Yunseok" last="Oh">Yunseok Oh</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Ryoo, Gongmi" sort="Ryoo, Gongmi" uniqKey="Ryoo G" first="Gongmi" last="Ryoo">Gongmi Ryoo</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Jeong, Yoo Seong" sort="Jeong, Yoo Seong" uniqKey="Jeong Y" first="Yoo-Seong" last="Jeong">Yoo-Seong Jeong</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Gadalla, Hytham H" sort="Gadalla, Hytham H" uniqKey="Gadalla H" first="Hytham H" last="Gadalla">Hytham H. Gadalla</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Min, Jee Sun" sort="Min, Jee Sun" uniqKey="Min J" first="Jee Sun" last="Min">Jee Sun Min</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083</wicri:regionArea><wicri:noRegion>Gyeonggi-do 42083</wicri:noRegion></affiliation></author><author><name sortKey="Jo, Jung Hwan" sort="Jo, Jung Hwan" uniqKey="Jo J" first="Jung Hwan" last="Jo">Jung Hwan Jo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Song, Myung Geun" sort="Song, Myung Geun" uniqKey="Song M" first="Myung Geun" last="Song">Myung Geun Song</name><affiliation wicri:level="1"><nlm:affiliation>Biomedical Research Institute, Seoul National University Hospital & Department of Nuclear Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biomedical Research Institute, Seoul National University Hospital & Department of Nuclear Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Kang, Keon Wook" sort="Kang, Keon Wook" uniqKey="Kang K" first="Keon Wook" last="Kang">Keon Wook Kang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Bae, Soo Kyung" sort="Bae, Soo Kyung" uniqKey="Bae S" first="Soo Kyung" last="Bae">Soo Kyung Bae</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083</wicri:regionArea><wicri:noRegion>Gyeonggi-do 42083</wicri:noRegion></affiliation></author><author><name sortKey="Yeo, Yoon" sort="Yeo, Yoon" uniqKey="Yeo Y" first="Yoon" last="Yeo">Yoon Yeo</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Dr, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Dr, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lee, Wooin" sort="Lee, Wooin" uniqKey="Lee W" first="Wooin" last="Lee">Wooin Lee</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea. Electronic address: wooin.lee@snu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30954620</idno><idno type="pmid">30954620</idno><idno type="doi">10.1016/j.jconrel.2019.04.006</idno><idno type="pmc">PMC6638563</idno><idno type="wicri:Area/Main/Corpus">000420</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000420</idno><idno type="wicri:Area/Main/Curation">000420</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000420</idno><idno type="wicri:Area/Main/Exploration">000420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.</title><author><name sortKey="Park, Ji Eun" sort="Park, Ji Eun" uniqKey="Park J" first="Ji Eun" last="Park">Ji Eun Park</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Park, Joonyoung" sort="Park, Joonyoung" uniqKey="Park J" first="Joonyoung" last="Park">Joonyoung Park</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Jun, Yearin" sort="Jun, Yearin" uniqKey="Jun Y" first="Yearin" last="Jun">Yearin Jun</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Oh, Yunseok" sort="Oh, Yunseok" uniqKey="Oh Y" first="Yunseok" last="Oh">Yunseok Oh</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Ryoo, Gongmi" sort="Ryoo, Gongmi" uniqKey="Ryoo G" first="Gongmi" last="Ryoo">Gongmi Ryoo</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Jeong, Yoo Seong" sort="Jeong, Yoo Seong" uniqKey="Jeong Y" first="Yoo-Seong" last="Jeong">Yoo-Seong Jeong</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Gadalla, Hytham H" sort="Gadalla, Hytham H" uniqKey="Gadalla H" first="Hytham H" last="Gadalla">Hytham H. Gadalla</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Min, Jee Sun" sort="Min, Jee Sun" uniqKey="Min J" first="Jee Sun" last="Min">Jee Sun Min</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083</wicri:regionArea><wicri:noRegion>Gyeonggi-do 42083</wicri:noRegion></affiliation></author><author><name sortKey="Jo, Jung Hwan" sort="Jo, Jung Hwan" uniqKey="Jo J" first="Jung Hwan" last="Jo">Jung Hwan Jo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Song, Myung Geun" sort="Song, Myung Geun" uniqKey="Song M" first="Myung Geun" last="Song">Myung Geun Song</name><affiliation wicri:level="1"><nlm:affiliation>Biomedical Research Institute, Seoul National University Hospital & Department of Nuclear Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Biomedical Research Institute, Seoul National University Hospital & Department of Nuclear Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Kang, Keon Wook" sort="Kang, Keon Wook" uniqKey="Kang K" first="Keon Wook" last="Kang">Keon Wook Kang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Bae, Soo Kyung" sort="Bae, Soo Kyung" uniqKey="Bae S" first="Soo Kyung" last="Bae">Soo Kyung Bae</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083</wicri:regionArea><wicri:noRegion>Gyeonggi-do 42083</wicri:noRegion></affiliation></author><author><name sortKey="Yeo, Yoon" sort="Yeo, Yoon" uniqKey="Yeo Y" first="Yoon" last="Yeo">Yoon Yeo</name><affiliation wicri:level="2"><nlm:affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Dr, West Lafayette, IN 47907, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Dr, West Lafayette, IN 47907</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lee, Wooin" sort="Lee, Wooin" uniqKey="Lee W" first="Wooin" last="Lee">Wooin Lee</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea. Electronic address: wooin.lee@snu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName><orgName type="university">Université nationale de Séoul</orgName><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of controlled release : official journal of the Controlled Release Society</title><idno type="eISSN">1873-4995</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albumins (chemistry)</term><term>Animals (MeSH)</term><term>Antineoplastic Agents (chemistry)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Biological Transport (MeSH)</term><term>Breast Neoplasms (drug therapy)</term><term>Cyclodextrins (chemistry)</term><term>Drug Carriers (chemistry)</term><term>Drug Compounding (MeSH)</term><term>Drug Liberation (MeSH)</term><term>Drug Stability (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Mice (MeSH)</term><term>Mice, Inbred BALB C (MeSH)</term><term>Nanoparticles (chemistry)</term><term>Oligopeptides (chemistry)</term><term>Oligopeptides (pharmacokinetics)</term><term>Oligopeptides (therapeutic use)</term><term>Poloxamer (chemistry)</term><term>Proteasome Inhibitors (chemistry)</term><term>Proteasome Inhibitors (therapeutic use)</term><term>Solubility (MeSH)</term><term>Surface Properties (MeSH)</term><term>Tissue Distribution (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albumines (composition chimique)</term><term>Animaux (MeSH)</term><term>Antinéoplasiques (composition chimique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Cyclodextrines (composition chimique)</term><term>Distribution tissulaire (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Inhibiteurs du protéasome (composition chimique)</term><term>Inhibiteurs du protéasome (usage thérapeutique)</term><term>Libération de médicament (MeSH)</term><term>Nanoparticules (composition chimique)</term><term>Oligopeptides (composition chimique)</term><term>Oligopeptides (pharmacocinétique)</term><term>Oligopeptides (usage thérapeutique)</term><term>Poloxamère (composition chimique)</term><term>Propriétés de surface (MeSH)</term><term>Préparation de médicament (MeSH)</term><term>Solubilité (MeSH)</term><term>Souris (MeSH)</term><term>Souris de lignée BALB C (MeSH)</term><term>Stabilité de médicament (MeSH)</term><term>Transport biologique (MeSH)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Vecteurs de médicaments (composition chimique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Albumins</term><term>Antineoplastic Agents</term><term>Cyclodextrins</term><term>Drug Carriers</term><term>Oligopeptides</term><term>Poloxamer</term><term>Proteasome Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Oligopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Oligopeptides</term><term>Proteasome Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Albumines</term><term>Antinéoplasiques</term><term>Cyclodextrines</term><term>Inhibiteurs du protéasome</term><term>Nanoparticules</term><term>Oligopeptides</term><term>Poloxamère</term><term>Vecteurs de médicaments</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Oligopeptides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs du protéasome</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Biological Transport</term><term>Drug Compounding</term><term>Drug Liberation</term><term>Drug Stability</term><term>Female</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Solubility</term><term>Surface Properties</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Distribution tissulaire</term><term>Femelle</term><term>Humains</term><term>Libération de médicament</term><term>Propriétés de surface</term><term>Préparation de médicament</term><term>Solubilité</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Stabilité de médicament</term><term>Transport biologique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbacks. We investigated whether a nanocrystal (NC) formulation can address these issues and enhance anticancer efficacy of CFZ against breast cancer. The surface of NC was coated with albumin in order to enhance the formulation stability and drug delivery to tumors via interactions with albumin-binding proteins located in and near cancer cells. The novel albumin-coated NC formulation of CFZ (CFZ-alb NC) displayed improved metabolic stability and enhanced cellular interactions, uptake and cytotoxic effects in breast cancer cells in vitro. Consistently, CFZ-alb NC showed greater anticancer efficacy in a murine 4T1 orthotopic breast cancer model than the currently used cyclodextrin-based formulation. Overall, our results demonstrate the potential of CFZ-alb NC as a viable formulation for breast cancer therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30954620</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>302</Volume><PubDate><Year>2019</Year><Month>05</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of controlled release : official journal of the Controlled Release Society</Title><ISOAbbreviation>J Control Release</ISOAbbreviation></Journal><ArticleTitle>Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.</ArticleTitle><Pagination><MedlinePgn>148-159</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-3659(19)30198-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2019.04.006</ELocationID><Abstract><AbstractText>Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbacks. We investigated whether a nanocrystal (NC) formulation can address these issues and enhance anticancer efficacy of CFZ against breast cancer. The surface of NC was coated with albumin in order to enhance the formulation stability and drug delivery to tumors via interactions with albumin-binding proteins located in and near cancer cells. The novel albumin-coated NC formulation of CFZ (CFZ-alb NC) displayed improved metabolic stability and enhanced cellular interactions, uptake and cytotoxic effects in breast cancer cells in vitro. Consistently, CFZ-alb NC showed greater anticancer efficacy in a murine 4T1 orthotopic breast cancer model than the currently used cyclodextrin-based formulation. Overall, our results demonstrate the potential of CFZ-alb NC as a viable formulation for breast cancer therapy.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ji Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joonyoung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Yearin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Yunseok</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryoo</LastName><ForeName>Gongmi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Yoo-Seong</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadalla</LastName><ForeName>Hytham H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Jee Sun</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Jung Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Myung Geun</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Seoul National University Hospital & Department of Nuclear Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Keon Wook</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine & Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Soo Kyung</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Integrated Research, Institute of Pharmaceutical Sciences, Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 42083, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Yoon</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Industrial and Physical Pharmacy, Purdue University, Heine Pharmacy Bldg, 575 W Stadium Ave, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Dr, West Lafayette, IN 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wooin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research, Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea. Electronic address: wooin.lee@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA232419</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB017791</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Control Release</MedlineTA><NlmUniqueID>8607908</NlmUniqueID><ISSNLinking>0168-3659</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003505">Cyclodextrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>106392-12-5</RegistryNumber><NameOfSubstance UI="D020442">Poloxamer</NameOfSubstance></Chemical><Chemical><RegistryNumber>72X6E3J5AR</RegistryNumber><NameOfSubstance UI="C524865">carfilzomib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003505" MajorTopicYN="N">Cyclodextrins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020442" MajorTopicYN="N">Poloxamer</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061988" MajorTopicYN="N">Proteasome Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Albumin</Keyword><Keyword MajorTopicYN="Y">Breast cancer</Keyword><Keyword MajorTopicYN="Y">Carfilzomib</Keyword><Keyword MajorTopicYN="Y">Nanocrystal</Keyword><Keyword MajorTopicYN="Y">Proteasome inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30954620</ArticleId><ArticleId IdType="pii">S0168-3659(19)30198-1</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2019.04.006</ArticleId><ArticleId IdType="pmc">PMC6638563</ArticleId><ArticleId IdType="mid">NIHMS1040898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Rev Cancer. 2005 Apr;5(4):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15803154</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2006 Jan;95(1):146-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16315221</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2006 Feb 15;12(4):1317-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16489089</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Nov 1;110(9):3281-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17591945</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2007 Jul 1;67(13):6383-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17616698</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Pathol. 2008 Jan;36(1):30-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18337219</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticancer Drugs. 2008 Oct;19(9):899-909</Citation><ArticleIdList><ArticleId IdType="pubmed">18766004</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Resist Updat. 2008 Dec;11(6):231-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18849185</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Oncol. 2009 May;2(2):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">19412420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2009 Dec;8(12):3234-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19934276</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2010 Aug;99(8):3542-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20564383</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation><ArticleIdList><ArticleId IdType="pubmed">21067385</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2011 May;78(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21266197</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Oncol. 2011 Jun;6(6):998-1005</Citation><ArticleIdList><ArticleId IdType="pubmed">21532503</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 2011 Oct;39(10):1873-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21752943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2011 Oct 3;8(5):1985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21812439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2012 Apr;341(1):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22235146</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2012 Feb;13(3):395-406</Citation><ArticleIdList><ArticleId IdType="pubmed">22263900</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2012 Oct;29(10):2887-901</Citation><ArticleIdList><ArticleId IdType="pubmed">22688901</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2012 Sep 1;18(17):4830-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22761464</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2012 Sep;158(6):739-48</Citation><ArticleIdList><ArticleId IdType="pubmed">22845873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23000897</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 2013 Jan;41(1):230-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23118326</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2013 Dec;1830(12):5526-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23639804</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2013 Nov;34(33):8521-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23932500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2013 Aug 12;24(2):182-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23948298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23975329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2014 Jun;63(6):974-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24067278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine (Lond). 2014 Jan;9(1):121-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24354814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Treat Rev. 2014 Jul;40(6):781-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24630735</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcinogenesis. 2014 May;35(5):967-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24675529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2014 Jun 2;11(6):1762-71</Citation><ArticleIdList><ArticleId IdType="pubmed">24766270</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2015 Mar 1;136(5):E359-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25220842</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Oncol. 2014 Aug;10(10):1795-807</Citation><ArticleIdList><ArticleId IdType="pubmed">25303058</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2014 Dec 28;196:113-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25312543</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vis Exp. 2015 Feb 08;(96):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25742185</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2015 Aug;59:66-76</Citation><ArticleIdList><ArticleId IdType="pubmed">25956852</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS J. 2015 Sep;17(5):1126-34</Citation><ArticleIdList><ArticleId IdType="pubmed">26104805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2015 Nov;11(8):1893-907</Citation><ArticleIdList><ArticleId IdType="pubmed">26282377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2015 Oct 8;163(2):506-19</Citation><ArticleIdList><ArticleId IdType="pubmed">26451490</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1989 Mar 31;159(3):1309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">2649098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Nanotechnol. 2015 Oct;11(10):1747-63</Citation><ArticleIdList><ArticleId IdType="pubmed">26502638</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2015 Dec;36(12):822-846</Citation><ArticleIdList><ArticleId IdType="pubmed">26538316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2016 Apr;15(4):680-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26832793</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2016 Mar;6(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">27006893</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Cancer Prev. 2016;17(S3):43-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27165206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2016 Jul;15(7):1452-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27196779</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2016 Sep 10;237:168-76</Citation><ArticleIdList><ArticleId IdType="pubmed">27417039</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Aug 5;353(6299):594-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27493187</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Rev Camb Philos Soc. 2017 Aug;92(3):1505-1520</Citation><ArticleIdList><ArticleId IdType="pubmed">27545872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Deliv. 2016 Oct;7(10):665-681</Citation><ArticleIdList><ArticleId IdType="pubmed">27790952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2017 Oct 10;263:90-101</Citation><ArticleIdList><ArticleId IdType="pubmed">28049022</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Nano. 2017 Feb 28;11(2):1397-1411</Citation><ArticleIdList><ArticleId IdType="pubmed">28075552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Chem Biol. 2017 Feb 16;24(2):218-230</Citation><ArticleIdList><ArticleId IdType="pubmed">28132893</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Mar 8;12(3):e0173247</Citation><ArticleIdList><ArticleId IdType="pubmed">28273121</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Hematol Oncol. 2017 Mar 22;6:7</Citation><ArticleIdList><ArticleId IdType="pubmed">28344858</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2017 May 30;524(1-2):248-256</Citation><ArticleIdList><ArticleId IdType="pubmed">28373104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2017 Dec 1;81:607-626</Citation><ArticleIdList><ArticleId IdType="pubmed">28888016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Biomed Anal. 2017 Nov 30;146:341-346</Citation><ArticleIdList><ArticleId IdType="pubmed">28918323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2018 Jan 29;:</Citation><ArticleIdList><ArticleId IdType="pubmed">29341617</ArticleId></ArticleIdList></Reference><Reference><Citation>Small. 2018 Apr;14(16):e1703670</Citation><ArticleIdList><ArticleId IdType="pubmed">29570231</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2018 Oct;180:206-224</Citation><ArticleIdList><ArticleId IdType="pubmed">30048910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1988 May 15;48(10):2641-58</Citation><ArticleIdList><ArticleId IdType="pubmed">3282647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1973 Jan;228(2):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">4687099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1995 Sep 1;55(17):3752-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7641188</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 1993 Jul;10(7):1093-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8378254</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Oncol Hematol. 1997 Jul;26(2):77-100</Citation><ArticleIdList><ArticleId IdType="pubmed">9298326</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9539785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li><li>États-Unis</li></country><region><li>Indiana</li><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement><orgName><li>Université nationale de Séoul</li></orgName></list><tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Park, Ji Eun" sort="Park, Ji Eun" uniqKey="Park J" first="Ji Eun" last="Park">Ji Eun Park</name></region><name sortKey="Bae, Soo Kyung" sort="Bae, Soo Kyung" uniqKey="Bae S" first="Soo Kyung" last="Bae">Soo Kyung Bae</name><name sortKey="Jeong, Yoo Seong" sort="Jeong, Yoo Seong" uniqKey="Jeong Y" first="Yoo-Seong" last="Jeong">Yoo-Seong Jeong</name><name sortKey="Jo, Jung Hwan" sort="Jo, Jung Hwan" uniqKey="Jo J" first="Jung Hwan" last="Jo">Jung Hwan Jo</name><name sortKey="Jun, Yearin" sort="Jun, Yearin" uniqKey="Jun Y" first="Yearin" last="Jun">Yearin Jun</name><name sortKey="Kang, Keon Wook" sort="Kang, Keon Wook" uniqKey="Kang K" first="Keon Wook" last="Kang">Keon Wook Kang</name><name sortKey="Lee, Wooin" sort="Lee, Wooin" uniqKey="Lee W" first="Wooin" last="Lee">Wooin Lee</name><name sortKey="Min, Jee Sun" sort="Min, Jee Sun" uniqKey="Min J" first="Jee Sun" last="Min">Jee Sun Min</name><name sortKey="Oh, Yunseok" sort="Oh, Yunseok" uniqKey="Oh Y" first="Yunseok" last="Oh">Yunseok Oh</name><name sortKey="Ryoo, Gongmi" sort="Ryoo, Gongmi" uniqKey="Ryoo G" first="Gongmi" last="Ryoo">Gongmi Ryoo</name><name sortKey="Song, Myung Geun" sort="Song, Myung Geun" uniqKey="Song M" first="Myung Geun" last="Song">Myung Geun Song</name></country><country name="États-Unis"><region name="Indiana"><name sortKey="Park, Joonyoung" sort="Park, Joonyoung" uniqKey="Park J" first="Joonyoung" last="Park">Joonyoung Park</name></region><name sortKey="Gadalla, Hytham H" sort="Gadalla, Hytham H" uniqKey="Gadalla H" first="Hytham H" last="Gadalla">Hytham H. Gadalla</name><name sortKey="Yeo, Yoon" sort="Yeo, Yoon" uniqKey="Yeo Y" first="Yoon" last="Yeo">Yoon Yeo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000446 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000446 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30954620
|texte= Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30954620" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |